Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep phenotyping and imiquimod challenge study in cutaneous lupus erythematosus
NL-OMON53201Recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Mar 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of imiquimod in cutaneous lupus erythematosus (CLE) (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Application site assessment, Vital signs and 23 more. Started Mar 2024; status: recruiting.
02
Drugs
imiquimod
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NL-OMON53201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53201.